Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Monoclonal Antibody Blocks B-Cell Receptor and Eases Leukemia Burden in Mouse Model

By BiotechDaily International staff writers
Posted on 26 May 2014
Blocking the B-cell-activating factor receptor (BAFF-R) on leukemia cells has been suggested as a new approach for treating an acute, chemotherapy-resistant form of childhood leukemia.

Acute lymphoblastic leukemia (ALL) is characterized by an excessive amount of white blood cell precursors (B-cell lymphoblasts) in the blood and bone marrow. B-cell lineage ALL (pre-B ALL) accounts for 80% to 85% of childhood ALL.

BAFF-R is encoded in humans by the TNFRSF13C (tumor necrosis factor receptor superfamily member 13C) gene. BAFF enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in their serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by the TNFRSF13C gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain.

It is thought that BAFF-R is the principal receptor required for BAFF-mediated mature B-cell survival. Since BAFF-R is expressed on precursor pre-B ALL cells but not on their pre-B normal counterparts, selective killing of ALL cells is possible by targeting this receptor.

Investigators at the University of Southern California (USA) tested a novel humanized anti–BAFF-R monoclonal antibody in a study carried out on leukemia cell cultures and in an immunodeficient mouse transplant model.

They reported in the May 13, 2014, online edition of the journal Molecular Cancer Therapeutics that the antibodies significantly stimulated natural killer cell-mediated killing of different human patient-derived ALL cells. Moreover, incubation of such ALL cells with these antibodies stimulated phagocytosis by macrophages. When this was tested in the immunodeficient transplant model, mice that were treated with the antibody had a significantly decreased leukemia burden in bone marrow and spleen.

"We have now demonstrated that BAFF-R is a strong potential therapeutic target for treating chemotherapy-resistant leukemia cells, without damaging healthy cells," said senior author Dr. Nora Heisterkamp, professor of research, pediatrics, and pathology at the University of Southern California. "We found that human pre-B ALL cells could be even further reduced when the anti-BAFF-R antibody was combined with chemotherapy or another therapeutic agent. We are looking at a potential one, two punch."

Related Links:

University of Southern California



Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.